newsfilter
← Latest News
GlobeNewswire·

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for